LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

Director / PDMR Shareholding

LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, has today been advised by Dr Terry O'Brien, Chief Executive Officer of the Company, that he has today transferred 292,185 ordinary shares of 0.5 pence each in the Company ("Ordinary Shares") into his Self Invested Personal Pension at a price of 13.69p per Ordinary Share.

Dr O'Brien is the principal beneficiary of this pension fund and following this transaction his beneficial interest in the Company remains unchanged at 11,516,563 Ordinary Shares which represents approximately 5.95% of the Company's issued share capital.

- ENDS -

For further information, please contact:

Media enquiries:

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.